而依据引起肿瘤细胞PD-L1表达的分子机制,可将PD-L1表达分为组成型PD-L1表达(constitutive PD-L1 expression)和诱导型PD-L1表达(inducible PD-L1 expression)。前者一般由肿瘤相关基因的变异所致,表现为肿瘤细胞PD-L1表达呈均一分布,与免疫治疗疗效相关性不...
Keytruda NSCLC Approval Will Test PD-L1 ExpressionEmily Hayes
pathologist‑based assessment of 4 immunohistochemistry assays for PD‑L1 expression in non‑small cell lung cancer[J]. JAMA Oncol, 2017, 3(8):1051‑1058. DOI: 10.1001/jamaoncol.2017.0013.[6]Xue, Liyan et al. “Concordance between four PD-L1 immunohistochemical assays and 22C3 pharmDx ...
[9] Munari E, Zamboni G, Lunardi G, et al. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. Hum Pathol. 2019;90:54-59. doi:10.1016/j.humpath.2019.05.003...
Shigeta N, Murakami S, Yokose T, et al. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thorac Cancer. 2024;15(17):1343-1349. doi:10.1111/1759-7714.15319 ...
PD-L1 expression predicts response to immune checkpoint inhibitors in renal cell carcinomas (RCC), but has also been suggested to be linked to poor patient
expression of PD-L1 in patients with esophageal squamous cell carcinoma (ESCC) and the consistency and correlation of IHC detection of seven different clones of PD-L1 antibody, and to provide reference for the gradual ...
increased (BCCA-test-con and MA31-con), revealing the inter pathologist variability. In addition to quality assurance, the system could be used to allow pathologists to spare IHC staining and interpretation from more than 70% of the patients while retaining 100% sensitivity for PD-L1 expression ...
Most ICIs target programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) axis with the aim of restoring antitumor immunity. Multiple clinical trials for ICIs have evaluated a predictive value of PD-L1 protein expression in tumor cells and tumor-infiltrating immune cells (...
a, PD-L1 expression, response and survival in all replication repair-deficient cancers. Cut-off is ≥ 1% of cells (median; Methods). b, CD8 expression, response and survival for replication repair-deficient cancers. Cut-off is ≥ 3% of cells (median; Methods). c, CD68 expression, response...